valine and docetaxel anhydrous

valine has been researched along with docetaxel anhydrous in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	4 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chung, LW; Fuji, K; Fujisawa, M; Gardner, TA; Gotoh, A; Hamada, K; Hara, I; Higashihara, E; Hinata, N; Kamidono, S; Kao, C; Matsuo, M; Okegawa, T; Shirakawa, T; Sugimura, K; Takenaka, A; Tanaka, K; Terao, S	1
Alexandre, J; Durand, JP; Goldwasser, F; Mir, O; Pons, G; Tran, A; Treluyer, JM	1
Chen, E; Christensen, JG; Fang, DD; John-Baptiste, A; Lira, ME; Painter, C; Yan, Z; Zhang, CC; Zhang, Q; Zong, Q	1
Cui, D; Dai, J; Keller, ET; Keller, JM; Mizokami, A; Xia, S	1
Aftimos, P; Awada, A; Cesari, R; Curigliano, G; Dees, EC; Huang, B; Jiang, Y; Kern, KA; Locatelli, MA; LoRusso, PM; Pegram, MD; Shaik, MN	1
Chen, Z; Du, Z; Hao, Y; Li, L; Li, T; Liu, N; Luo, C; Quan, Z; Sun, W; Wang, J; Wang, X; Wu, X; Yuan, M; Zhang, Y	1

Trials

2 trial(s) available for valine and docetaxel anhydrous

Article	Year
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Human gene therapy, 2007, Volume: 18, Issue:12 Topics: Acyclovir; Adenoviridae; Aged; Androgen Antagonists; Antineoplastic Agents; Antiviral Agents; Bone and Bones; Bone Neoplasms; Docetaxel; Genetic Therapy; Genetic Vectors; Humans; Male; Middle Aged; Osteocalcin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Thymidine Kinase; Valacyclovir; Valine	2007
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget, 2017, Jan-10, Volume: 8, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tetrahydronaphthalenes; Triple Negative Breast Neoplasms; Valine; Vomiting	2017

Article

Year

Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.

Human gene therapy, 2007, Volume: 18, Issue:12

Topics: Acyclovir; Adenoviridae; Aged; Androgen Antagonists; Antineoplastic Agents; Antiviral Agents; Bone and Bones; Bone Neoplasms; Docetaxel; Genetic Therapy; Genetic Vectors; Humans; Male; Middle Aged; Osteocalcin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Thymidine Kinase; Valacyclovir; Valine

2007

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Oncotarget, 2017, Jan-10, Volume: 8, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tetrahydronaphthalenes; Triple Negative Breast Neoplasms; Valine; Vomiting

2017

Other Studies

4 other study(ies) available for valine and docetaxel anhydrous

Article	Year
Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Glutathione Transferase; Humans; Isoleucine; Male; Middle Aged; Oxidative Stress; Peripheral Nervous System Diseases; Polymorphism, Genetic; Taxoids; Valine	2009
Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem cells translational medicine, 2013, Volume: 2, Issue:3 Topics: AC133 Antigen; Amyloid Precursor Protein Secretases; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Hyaluronan Receptors; Membrane Proteins; Mice; Mice, SCID; Multidrug Resistance-Associated Protein 2; Nerve Tissue Proteins; Peptides; Receptor, Notch1; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Time Factors; Valine; Xenograft Model Antitumor Assays	2013
Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-15, Volume: 21, Issue:20 Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Inbred NOD; NF-kappa B; Prostatic Neoplasms; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays	2015
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in International journal of oncology, 2018, Volume: 53, Issue:1 Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Proteins; Receptors, Notch; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays	2018